Last reviewed · How we verify
clomiphene plus gonadotropins
At a glance
| Generic name | clomiphene plus gonadotropins |
|---|---|
| Also known as | Clomid. Serophene. Gonal f. Bravelle. Follistim. Menopur. |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
- LE + CC vs. LE for Ovulation Induction (NA)
- Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation (PHASE4)
- Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females (PHASE3)
- Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders (EARLY_PHASE1)
- Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study (PHASE4)
- Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clomiphene plus gonadotropins CI brief — competitive landscape report
- clomiphene plus gonadotropins updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI